1 / 29

Nanomedicines

Nanomedicines. Nanomedicines for diagnosis and therapy. Materials for nano -medicines. Importance of nanomedicine for cancer treatments. RES: An older term for the mononuclear phagocyte system.

ria-mullen
Download Presentation

Nanomedicines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nanomedicines

  2. Nanomedicines for diagnosis and therapy

  3. Materials for nano-medicines

  4. Importance of nanomedicine for cancer treatments RES: An older term for the mononuclear phagocyte system - A part of the immune system that consists of the phagocytic cells located in reticular connective tissue. - The cells are primarily monocytes and macrophages, and they accumulate in lymph nodes and the spleen.

  5. Nano-carriers for drug delivery

  6. Liposomes

  7. Advantages of liposome structure

  8. Polysomes

  9. Polymeric micells

  10. Amphiphilic polymers for micells

  11. Advantage of polymeric micells

  12. Drug release from polymeric micells

  13. Other types of polymeric micells

  14. Dendrimers

  15. Advantages of dendrimers

  16. Hydrogel nanoparticles

  17. Stealth effect of PEGs

  18. Doxorubicine-EG-Folate modified micells

  19. Doxorubicin

  20. Liposome products

  21. Angiogenesis in cancers

  22. ERP (Enhanced permeability and retention) effect

  23. Leaky blood vessels in tumors

  24. Passive tumor targeting by EPR effect

  25. Tumor targeting in nano-medicines

  26. Barriers in in-vivo implementation

  27. Lipid emulsion

More Related